Introduction {#section5-1753465816684424}
============

Idiopathic pulmonary arterial hypertension (IPAH) is a complex condition with multifactorial pathophysiology. While new developments regarding epidemiology and therapeutic options in IPAH are being reported \[[@bibr10-1753465816684424]; [@bibr11-1753465816684424]\], one important question has emerged over the years: how does a sex difference in the incidence of this disease reflect disease severity? Identified as the earliest modifier in all the epidemiological studies, IPAH occurs predominantly in females \[[@bibr5-1753465816684424]\], with incidence of 1.9- to 10-fold higher, depending on a specific subtype and registry of patients \[[@bibr24-1753465816684424]\]. With regards prognosis, the influence of sex is reversed \[[@bibr26-1753465816684424]\]. Both the French and the US-based registry \[Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)\], characterized prognostic indicators and concluded that males have worse outcomes \[[@bibr6-1753465816684424]; [@bibr19-1753465816684424]\]. In recent years, many studies have already demonstrated sex affects some signal pathways in the development of PAH \[[@bibr14-1753465816684424]; [@bibr17-1753465816684424]; [@bibr31-1753465816684424]\], although the majority of studies demonstrate effects of sex difference on cause, treatment and survival in PAH \[[@bibr18-1753465816684424]\]. The hypothesis we propose is that sex differences exist in the prognostic assessment indexes of the same test method. However, to date, there is no clear consensus of whether sex difference has an impact on alteration of exercise capacity, metabolism, ventilation, cardiovascular and gas exchange parameters in patients with IPAH. Gas exchange measurements during cardiopulmonary exercise testing (CPET) must be looked at with regards to cellular respiration and how cardiopulmonary mechanisms are coupled to it. Most IPAH patients have gas exchange limitations attributed to an impaired vasodilator response of the pulmonary arteries to exercise \[[@bibr30-1753465816684424]\]. CPET describes the underlying physiologic abnormalities associated with the hypoperfusion of the pulmonary vascular bed in IPAH \[[@bibr22-1753465816684424]\], which has been used to gain insights into exertional abnormalities in patients with PAH for decades. Exercise limitations in PAH are the result of dysfunctions from various physiological systems and CPET has been used extensively for evaluating these dysfunctions. This is central to some recently published important reviews \[[@bibr23-1753465816684424]; [@bibr4-1753465816684424]\]. Usefulness of CPET owes to its ability to uncover abnormalities in the VO~2~ cascade \[Sherry *et al.* 2016\]. Additionally, CPEt allows reproducible assessment of functional capacity and treatment efficacy in patients with IPAH \[[@bibr34-1753465816684424]\]. There are massive differences in CPET parameters between healthy male and female subjects, but whether these differences are replicated in patients with IPAH is still unclear. In addition, whether different CPET parameters can predict outcomes in male and female patients with IPAH is also unknown.

Thus, the objectives of the present study were to explore whether sex difference has an impact on alteration of CPET parameters in patients with incident IPAH and to correlate CPET measurements with hemodynamic variables as measured by right-heart catheterization (RHC).

Methods {#section6-1753465816684424}
=======

Population study {#section7-1753465816684424}
----------------

From May 2010 to February 2016, 83 patients (30 males, 53 females) with incident IPAH, aged more than 18-years old, were evaluated at Shanghai Pulmonary Hospital, Shanghai. The diagnosis of IPAH was established according to the most recent pulmonary hypertension guidelines, specifically, by the presence of a mean pulmonary arterial pressure (mPAP) \> 25 mmHg and a pulmonary capillary wedge pressure (PCWP) ⩽ 15 mm Hg, as assessed by RHC \[[@bibr10-1753465816684424]\]. Patients with PAH associated with a definite cause, such as connective tissue disease and congenital heart disease, and those with portopulmonary hypertension, chronic pulmonary obstruction, chronic pulmonary thromboembolism and pulmonary hypertension due to left heart disease were excluded. We also excluded patients with acute or chronic illnesses that might influence hormonal metabolism (i.e. acute or chronic infections, chronic autoimmune diseases, previously established primary endocrine disorders), and patients receiving any hormonal treatment (thyroid hormones, anabolic steroids, corticosteroids) or drugs that markedly inhibit hormone production, either at the time of the study or in the past.

The study protocol was reviewed and approved by the Ethics Committee of Shanghai Pulmonary Hospital (Ethics Approval No.: K12-089). Written informed consent was obtained from each patient for inclusion into the study and prior to the performance of any study-related procedures.

Assessment of patients {#section8-1753465816684424}
----------------------

Patients underwent RHC and a 6-minute walk distance (6MWD) test within 3 months of each patient's CPET study, their World Health Organization functional class (WHO FC) and N-terminal Natriuretic peptide type-B (NT-proBNP) were determined. RHC was performed following standard protocols \[[@bibr13-1753465816684424]\]. The 6MWD test was performed according to American Thoracic Society guidelines \[[@bibr1-1753465816684424]\], and a Borg dyspnea score was determined immediately after the 6MWD test. Immediately prior to their CPET studies, patients had standard pulmonary function tests.

Each patient performed a physician-supervised, standard, progressively increasing work rate CPET to maximum tolerance on an electromagnetically braked cycle ergometer. The protocol comprised of 3 minutes of rest, 3 minutes of unloaded cycling at 55--65 revolutions per minute (rpm), followed by a progressively increasing work rate of 5--15 Watts (W)/minute for PH patients and 20--25 W/minute for the normal subjects to the maximum tolerance, and 4 minutes of recovery \[[@bibr28-1753465816684424]\]. Pulse oximetry, heart rate (HR), 12-lead electrocardiography, and cuff blood pressure were monitored and recorded. Minute ventilation (VE, BTPS), maximum oxygen consumption (VO~2~, STPD), carbon dioxide output (VCO~2~, STPD), and other exercise variables were computer calculated breath by breath, interpolated second by second, and averaged over 10-second intervals \[[@bibr28-1753465816684424]\]. The anaerobic threshold (AT) ratio of oxygen pulse (O~2~ pulse) was determined as previously described \[[@bibr16-1753465816684424]\]. Exercise, metabolic and cardiovascular capacity were expressed as workload, VO~2~, O~2~ pulse and HR respectively. Ventilatory efficiency during exercise was expressed as VCO~2~, VE, the ratio of VO~2~/VE, VE/VCO~2~ (oxygen uptake efficiency plateau) OUEP, oxygen uptake efficiency slope (OUES) and the slope of VE *versus* VCO~2~ over the linear component of the plot of VE *versus* VCO~2~ \[[@bibr27-1753465816684424]\]. Gas exchange efficiency was expressed as carbon dioxide elimination/oxygen consumption (RER) and end-tidal partial pressure of CO~2~ (P~ET~CO~2~). The rate of VO~2~ increase during unloaded cycling was expressed as the mean response time (MRT) for a monoexponential curve fit to the second-by-second VO~2~ measurements during the 3 minutes of unloaded cycling \[[@bibr29-1753465816684424]\]. If the first breath VO~2~ equaled the 3-minute VO~2~, the MRT was considered equal to the duration of the first breath.

Statistical analysis {#section9-1753465816684424}
--------------------

Results are expressed as mean with standard deviation (SD) or medians (and interquartile range) for continuous variables and absolute number for categorical variables. The sample size and the power were analyzed by NCSS-PASS (© Copyright 2011 NCSS LLC., Kaysville, UT) version 11.0.7. Comparisons were performed using Student's *t* test or Mann--Whitney *U* test, for continuous variables and chi-square test for categorical variables. Correlations were assessed using Spearman's rank correlation coefficient. To determine the strength of the association found between hemodynamic and CPET variables found to correlate with IPAH at univariate analysis, we performed forward/backward multiple stepwise regression analysis with hemodynamic variables as the dependent outcome. We forced age, body mass index (BMI) and WHO FC into the models to adjust multiple regression analysis. *p* values \< 0.05 were considered significant. The main analysis was performed using SPSS (Statistic Package for Social Science, Chicago, IL) version 19.0.

Results {#section10-1753465816684424}
=======

Patient population {#section11-1753465816684424}
------------------

Demographics, baseline and hemodynamic data are illustrated in [Table 1](#table1-1753465816684424){ref-type="table"}. There was no difference in BMI between the two sexes and age was almost matched with mean age of 39.6 ± 17.2 years in males and 37.5 ± 12.0 years in females. A total of 83 patients had WHO FC reported at diagnosis. Yet there were no differences in overall WHO FC between the two groups. Men and women had similar absolute 6MWD and NT pro-BNP levels and mean right-arterial pressure (mRAP), mPAP, mean pulmonary capillary wedge pressure (mPAWP), pulmonary vascular resistance (PVR), CO and mixed venous O~2~ saturation at diagnosis were also similar between the two sexes. The differences of the treatment between the two sexes were not found either.

###### 

Baseline characteristics of all patients with idiopathic pulmonary arterial hypertension.

![](10.1177_1753465816684424-table1)

  ------------------------------------------------------------------------------------------
                            All\              Men\             Women\            *p* value
                            (*n* = 83)        (*n* = 30)       (*n* = 53)        
  ------------------------- ----------------- ---------------- ----------------- -----------
  **Clinical variables**                                                         

   Age, y                   38\. ± 14.0       39.6 ± 17.2      37.5 ± 12.0       0.547

   BMI, kg/m^2^             22.6 ± 3.1        23.0 ± 3.2       22.4 ± 3.0        0.457

   WHO-FC, *n* (%)                                                               0.494

   I--II                    48 (57.8)         19 (63.3)        29 (54.7)         

   III--IV                  35 (42.2)         11 (36.7)        24 (45.3)         

   6MWD, m                  399.0 ± 118.2     406.6 ± 125.4    394.4 ± 115.0     0.689

   NT pro-BNP, pg/ml        334 (167, 1096)   186 (23, 1096)   524 (155, 1226)   0.395

  **Hemodynamics**                                                               

   mRAP, mmHg               5.7 ± 4.3         6.4 ± 5.0        5.3 ± 3.7         0.270

   mPAP, mmHg               58.1 ± 13.8       57.7 ± 16.0      58.3 ± 12.5       0.867

   mPAWP, mmHg              7.2 ± 3.4         7.6 ± 2.2        6.9 ± 4.0         0.320

   PVR, Wood units          13.0 ± 5.7        11.9 ± 5.6       13.5 ± 5.7        0.222

   CO, l/min                4.6 ± 1.6         4.8 ± 1.8        4.4 ± 1.4         0.375

   SVO~2~, %                64.8 ± 10.1       63.2 ± 10.2      66.0 ± 10.0       0.310

  **Treatment**                                                                  **0.618**

  Specific medications                                                           

   PDE-5 inhibitors, %      35 (42.2)         12 (40.0)        23 (43.4)         

   ERAs, %                  15 (18.1)         4 (13.3)         11 (20.8)         

   Prostacyclin analog, %   4 (4.8)           1 (3.3)          3 (5.7)           

   Combination, %           22 (26.5)         11 (36.7)        11 (20.8)         

  No specific medication    4 (4.8)           2 (6.7)          2 (3.8)           
  ------------------------------------------------------------------------------------------

Values are mean (SD) or median (interquartile range).

6MWD, 6-minute walk distance; BMI, body mass index; CO, cardiac output; ERAs, endothelial receptor antagonists; mPAP, mean pulmonary arterial pressure; mPAWP, mean pulmonary capillary wedge pressure; mRAP, mean right arterial pressure; NT pro-BNP, N-Terminal pro-brain natriuretic peptide; PDE-5, phosphodiesterase type 5; PVR, pulmonary vascular resistance; SVO~2~, mixed venous O~2~ saturation; WHO-FC, World Health Organization functional class.

Sex differences of cardiopulmonary exercise testing parameters in patients with idiopathic pulmonary arterial hypertension {#section12-1753465816684424}
--------------------------------------------------------------------------------------------------------------------------

CPET results are presented in [Table 2](#table2-1753465816684424){ref-type="table"}. Peak workload and the metabolic parameter, that is, peak VO~2~ and AT was significantly higher in male patients with IPAH. Male patients also had higher peak VE and peak VCO~2~. OUES, representing gas exchange indices, was also higher in male IPAH patients than females. Peak O~2~ pulse, one of the cardiovascular parameters, also showed significantly higher levels in males than females. OUEP, VE *versus* VCO~2~ slope, peak HR, peak RER, peak P~ET~CO~2~ and P~ET~CO~2~ at AT were not significantly different between male and female IPAH patients. [Figure 1](#fig1-1753465816684424){ref-type="fig"} contrasts key CPET measurement differences and frequencies between the two groups.

###### 

Cardiopulmonary exercise testing parameters between male and female patients with idiopathic pulmonary arterial hypertension.

![](10.1177_1753465816684424-table2)

  -----------------------------------------------------------------------------------------------
  Variables                          All\            Men\             Women\          *p* value
                                     (*n* = 83)      (*n* = 30)       (*n* = 53)      
  ---------------------------------- --------------- ---------------- --------------- -----------
  **Exercise capacity parameters**                                                    

   Peak workload, Watts              72.4 ± 29.4     82.0 ± 36.1      67.0 ± 23.6     0.046

   Metabolic parameters                                                               

   Peak VO~2~, ml/min/kg             14.6 ± 4.9      16.3 ± 6.1       13.6 ± 3.8      0.032

   AT, ml/min/kg                     10.7 ± 3.2      12.1 ± 3.8       9.9 ± 2.6       0.002

  **Ventilatory parameters**                                                          

   Peak VE, l/min                    44.4 ± 13.3     53.0 ± 13.1      39.5 ± 10.9     \<0.001

   Peak VCO~2~, ml/min               910.5 ± 333.1   1046.2 ± 403.0   833.5 ± 260.2   0.013

   OUES, l/min/log                   1.1 ± 0.5       1.2 ± 0.5        1.0 ± 0.4       0.007

   OUEP, ml/l                        27.4 ± 7.2      27.9 ± 9.8       27.1 ± 5.2      0.645

   VE/VCO~2~ slope                   52.4 ± 26.9     58.8 ± 37.9      48.8 ± 17.4     0.102

  **Cardiovascular parameters**                                                       

   Peak O~2~ pulse, ml/beat          6.1 ± 2.0       6.8± 2.3         5.6 ± 1.7       0.009

   Peak HR, beats/min                142.4 ± 24.7    141.7 ± 28.1     142.7 ± 22.8    0.850

  **Gas exchange parameters**                                                         

   Peak RER                          1.1 ± 0.1       1.1 ± 0.1        1.1 ± 0.1       0.443

   Peak P~ET~CO~2~, mmHg             25.4 ± 6.8      24.4 ± 7.4       26.0 ± 6.3      0.316

   P~ET~CO~2~ at AT, mmHg            28.0 ± 6.8      27.0 ± 7.3       28.6 ± 6.4      0.305
  -----------------------------------------------------------------------------------------------

Values are mean (SD).

AT, anaerobic threshold; IPAH, idiopathic pulmonary arterial hypertension; OUEP, oxygen uptake efficiency plateau; OUES, oxygen uptake efficiency slope; P~ET~CO~2~, end-tidal partial pressure of CO~2~; PVR, pulmonary vascular resistance; RER, carbon dioxide elimination/oxygen consumption; VCO~2~, carbon dioxide output; VE, minute ventilation; VO~2~, oxygen uptake.

![Cardiopulmonary exercise testing parameters in male and female idiopathic pulmonary arterial hypertension patients.\
AT, anaerobic threshold; OUES, oxygen uptake efficiency slope; VCO~2~, carbon dioxide output; VE, minute ventilation; VO~2~, oxygen uptake.](10.1177_1753465816684424-fig1){#fig1-1753465816684424}

Relationship between cardiopulmonary exercise testing and hemodynamic parameters in patients with idiopathic pulmonary arterial hypertension {#section13-1753465816684424}
--------------------------------------------------------------------------------------------------------------------------------------------

Correlations between CPET parameters and hemodynamics are illustrated in [Tables 3](#table3-1753465816684424){ref-type="table"} and [4](#table4-1753465816684424){ref-type="table"}. Peak workload, peak VO~2~, AT, peak VCO~2~, OUES, peak O~2~ pulse, peak P~ET~CO~2~ and P~ET~CO~2~ at AT had significant negative correlations with PVR in all IPAH patients. Peak VO~2~, peak VCO~2~, OUES, peak O~2~ pulse, peak P~ET~CO~2~ and P~ET~CO~2~ at AT were negatively correlated to PVR in males, while only peak O~2~ pulse negatively correlated with PVR in females only. Only VE/VCO~2~ slope had significant positive correlation with PVR in all IPAH patients as a whole or in male patients when comparing them as three separate groups.

###### 

Correlations of cardiopulmonary exercise testing parameters to pulmonary vascular resistance in patients with idiopathic pulmonary arterial hypertension.

![](10.1177_1753465816684424-table3)

  --------------------------------------------------------------------------------------------------
  Variables                          All\         Men\         Women\                        
                                     (*n* = 83)   (*n* = 30)   (*n* = 53)                    
  ---------------------------------- ------------ ------------ ------------ ------- -------- -------
  **Exercise capacity parameters**                                                           

   Peak workload, Watts              −0.133       0.233        −0.150       0.430   −0.068   0.631

  **Metabolic parameters**                                                                   

   Peak VO~2~, ml/min/kg             −0.289       0.009        −0.329       0.006   −0.222   0.114

   AT, ml/min/kg                     −0.186       0.095        −0.192       0.308   −0.121   0.394

  **Ventilatory parameters**                                                                 

   Peak VE, l/min                    0.004        0.973        0.173        0.361   0.023    0.871

   Peak VCO~2~, ml/min               −0.290       0.008        −0.266       0.015   −0.273   0.051

   OUES, l/min/log                   −0.290       0.009        −0.429       0.018   −0.149   0.301

   OUEP, ml/l                        −0.094       0.402        0.152        0.438   −0.352   0.051

   VE/VCO~2~ slope                   0.260        0.018        0.352        0.044   0.270    0.053

  **Cardiovascular parameters**                                                              

   Peak O~2~ pulse, ml/beat          −0.386       \<0.001      −0.336       0.009   −0.393   0.004

   Peak HR, beats/min                0.141        0.207        0.127        0.504   0.153    0.279

  **Gas exchange parameters**                                                                

   Peak RER                          0.105        0.361        0.107        0.595   0.131    0.359

   Peak P~ET~CO~2~, mmHg             −0.349       0.001        −0.445       0.014   −0.324   0.059

   P~ET~CO~2~ at AT, mmHg            −0.300       0.006        −0.340       0.016   −0.308   0.056
  --------------------------------------------------------------------------------------------------

Data are Spearman's rank correlation coefficient or Pearson.

AT, anaerobic threshold; OUEP, oxygen uptake efficiency plateau; OUES, oxygen uptake efficiency slope; P~ET~CO~2~, end-tidal partial pressure of CO~2~; PVR, pulmonary vascular resistance; VCO~2~, carbon dioxide output; VE, minute ventilation; VO~2~, maximum oxygen consumption; HR, heart rate; RER, carbon dioxide elimination/oxygen consumption.

###### 

Correlations of cardiopulmonary exercise testing parameters to cardiac output in patients with idiopathic pulmonary arterial hypertension.

![](10.1177_1753465816684424-table4)

  ----------------------------------------------------------------------------------------------------
  Variables                          All\         Men\         Women\                          
                                     (*n* = 83)   (*n* = 30)   (*n* = 53)                      
  ---------------------------------- ------------ ------------ ------------ --------- -------- -------
  **Exercise capacity parameters**                                                             

   Peak workload, Watts              0.238        0.032        0.312        0.094     0.121    0.391

  **Metabolic parameters**                                                                     

   Peak VO~2~, ml/min/kg             0.433        \<0.001      0.612        \<0.001   0.209    0.137

   AT, ml/min/kg                     0.318        0.004        0.474        0.008     0.126    0.373

  **Ventilatory parameters**                                                                   

   Peak VE, l/min                    0.287        0.059        0.037        0.847     0.482    0.050

   Peak VCO~2~, ml/min               0.444        \<0.001      0.432        0.017     0.447    0.001

   OUES, l/min/log                   0.372        0.001        0.448        0.013     0.280    0.051

   OUEP, ml/l                        0.170        0.128        0.213        0.258     0.110    0.480

   VE/VCO~2~ slope                   −0.188       0.045        −0.278       0.137     −0.122   0.388

  **Cardiovascular parameters**                                                                

   Peak O~2~ pulse, ml/beat          0.379        \<0.001      0.341        0.065     0.393    0.001

   Peak HR, beats/min                −0.076       0.500        0.141        0.457     −0.021   0.881

  **Gas exchange parameters**                                                                  

   Peak RER                          −0.055       0.634        −0.046       0.820     −0.078   0.588

   Peak P~ET~CO~2~, mmHg             0.199        0.033        0.441        0.015     0.020    0.890

   P~ET~CO~2~ at AT, mmHg            0.196        0.037        0.391        0.032     0.061    0.666
  ----------------------------------------------------------------------------------------------------

Data are Spearman's rank correlation coefficient or Pearson.

AT, anaerobic threshold; OUEP, oxygen uptake efficiency plateau; OUES, oxygen uptake efficiency slope; P~ET~CO~2~, end-tidal partial pressure of CO~2~; VCO~2~, carbon dioxide output; VE, minute ventilation; VO~2~, maximum oxygen consumption; HR, heart rate; RER, carbon dioxide elimination/oxygen consumption.

Peak workload, peak VO~2~, AT, peak VCO~2~, OUES, peak O~2~ pulse, peak P~ET~CO~2~ and P~ET~CO~2~ at AT correlated positively with CO in all patients. Peak VO~2~, AT, peak VCO~2~, OUES, peak P~ET~CO~2~ and P~ET~CO~2~ at AT correlated positively with CO in male IPAH patients. Meanwhile, peak VCO~2~ and peak O~2~ pulse correlated positively with CO in female group. Only VE/VCO~2~ slope had significant negative correlation with CO in all IPAH patients.

Factors influencing pulmonary ventilation rate and cardiac output {#section14-1753465816684424}
-----------------------------------------------------------------

Significantly correlated variables were entered into stepwise multiple regression analyses to determine the strength of each individual parameter to predict PVR elevation. As shown in [Table 5](#table5-1753465816684424){ref-type="table"}, for the whole 83 IPAH patients, the model 1 adjusted by age, gender, BMI and WHO FC, peak P~ET~CO~2~ was an independent predictor and explained 12.2% (*R*^2^ = 0.122) of the variation in this measurement. In male IPAH patients, model 2 adjusted by age, BMI and WHO FC, peak P~ET~CO~2~ was the independent predictor accounting for 19.8% (*R*^2^ = 0.198) of the variation. In the females, model 2, peak O~2~ pulse was the sole independent predictor of PVR, separately accounting for 15.5% (*R*^2^ = 0.155) of the variation.

###### 

Determinants of pulmonary vascular resistance and cardiac output in all idiopathic pulmonary arterial hypertension patients.

![](10.1177_1753465816684424-table5)

  ------------------------------------------------------------------------------------------------------------------------
  Populations studied            Model     Independent variables   *R* ^2^   Standardized β   95% CI           *p* value
  ------------------------------ --------- ----------------------- --------- ---------------- ---------------- -----------
  **Dependent variables: PVR**                                                                                 

   All patients\                 Model 1   Peak P~ET~CO~2~         0.122     −0.291           −0.465\~−0.117   0.001
  (*n* = 83)                                                                                                   

   Male patients\                Model 2   Peak P~ET~CO~2~         0.198     −0.33            −0.592\~−0.073   0.014
  (*n* = 30)                                                                                                   

   Female patients\              Model 2   Peak O~2~ pulse         0.155     −1.271           −2.115\~−0.428   0.004
  (*n* = 53)                                                                                                   

  **Dependent variables: CO**                                                                                  

   All patients\                 Model 1   Peak VO~2~              0.187     0.138            0.074\~0.202     \<0.001
  (*n* = 83)                                                                                                   

   Male patients\                Model 2   Peak VO~2~              0.375     0.181            0.091\~0.272     \<0.001
  (*n* = 30)                                                                                                   

   Female patients\              Model 2   Peak O~2~ pulse         0.155     0.317            0.106\~0.527     0.004
  (*n* = 53)                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------

Model 1, adjust for age, sex, BMI and WHO FC; Model 2, adjust for age, BMI and WHO FC;

CI, confidence interval; P~ET~CO~2~, end-tidal partial pressure of CO~2~; VO~2~, maximum oxygen consumption, PVR, pulmonary vascular resistance; CO cardiac output.

Peak VO~2~ was the sole independent predictor of CO decline and accounted for 18.7% (*R*^2^ = 0.187) of the variations in this measurement for all IPAH patients (associated model 1) and 37.5% (*R*^2^ = 0.375) in male patients (associated model 2). In female patients, model 2, peak O~2~ pulse was the sole independent predictor of CO accounting for 15.5% (*R*^2^ = 0.155) of the variation.

Discussion {#section15-1753465816684424}
==========

CPET's increasing credibility is reflected by the fact that major guidelines for the treatment and management of PAH have endorsed it \[[@bibr8-1753465816684424]\]. Evidence since the last 2 decades and beyond have already established that there are differences in exercise capacities between the two sexes \[[@bibr2-1753465816684424]; [@bibr3-1753465816684424]; [@bibr7-1753465816684424]\]. Also, work efficiency in humans is relatively fixed for a given work task as well. While race, body build and genetic predispositions can all influence exercise capacity, how a differently reduced exercise capacity between the two sexes reflects impaired hemodynamics is still not clear \[[@bibr32-1753465816684424]\]. It has been well established that VO~2~/kg fairly represents metabolic demand. Both peak VO~2~ and VE/VCO~2~ slope and their predicted normal for a particular patient would be fairly accurate in terms of their predictive ability \[[@bibr21-1753465816684424]; [@bibr25-1753465816684424]\]. The current paper perhaps is the first to report that a relationship between CPET parameters and PVR as well as CO exists in IPAH. Sex differences of CPET parameters have received far less attention than hemodynamic parameters in IPAH. We hope this paper will serve its purpose of trying to reason why the difference in exercise capacities affects hemodynamics in a particular disease spectrum, in this case, IPAH. Although being an initial small sample study (*n* = 83), several CPET indexes reflected 'sex-specific' differences and some of them were able to predict PVR and CO independently.

There were no significant sex differences in WHO-FC, 6MWD, NT-proBNP or hemodynamics at the time of diagnosis and treatment in our study, but higher trends of mPAP, mRAP, CO and 6MWD in men were visible, implying that men with IPAH have relatively lower pulmonary vascular function, yet higher cardiovascular function and exercise ability. Thus, sex may affect the hemodynamics in our study. The REVEAL Registry indicated that male PAH patients categorized as New York Heart Association Functional Classification I-II (NYHA FCI-II), had higher mPAP, mRAP, CO and 6MWD at diagnosis \[[@bibr26-1753465816684424]\].Their results are not completely consistent with ours. One possible reason is our small sample size, while the REVEAL Registry included 2969 patients, which is a large sample study. Another possible reason is that they classified patients differently, that is, patients in our study labeled as IPAH, are classified as IPAH, FPAH, CTD-PAH, CHD-PAH and other associated PAH subgroups in the REVEAL Registry \[[@bibr26-1753465816684424]\].

The actual values for all CPET variables were compared between the two sexes because predicted values are often adjusted for some factors, that is, sex. Jarvis and colleagues demonstrated that differences in muscle mass, fiber type or the way energy production takes place in the two sexes in healthy humans, suggesting male IPAH patients demonstrate higher metabolism and ventilation compared with female patients \[[@bibr12-1753465816684424]\]. Our data indicate that exercise capacity, metabolic, ventilatory and cardiovascular parameters, the four key aspects of any CPET, were all higher in male IPAH patients than in females. As described above, perhaps a larger muscle mass, as seen in males, is a reason that male patients probably have better cardiovascular and exercise pliability. The role of sex hormones in causation of IPAH may be another key factor as well when interpreting these sex differences. Sex hormones, especially estradiol and its metabolites, may affect metabolic enzymes, some signal pathway and epigenetics in cardiopulmonary vascular systems \[[@bibr14-1753465816684424]; [@bibr17-1753465816684424]; [@bibr31-1753465816684424]\]. In either case, severe limitations are seen with cardiopulmonary function in female patients with IPAH.

CPET with gas exchange measurements has the potential of noninvasively grading the severity of exercise limitation, quantifying the hypoperfusion of the lung and systemic circulation, and assessing responses to treatment before overt right ventricular failure, and PAH is evident even at rest \[[@bibr33-1753465816684424]; [@bibr35-1753465816684424]\]. Pinkstaff and colleagues go even further by making class recommendations for CPET, for diagnostic evaluation (Level B, Class IIa), prognostication (Level B, class IIb) and determining therapeutic efficiency (Level C, class IIb) \[[@bibr23-1753465816684424]\].

The continued PVR elevation in IPAH due to progressive pulmonary vasculopathy, limits blood flow through the lung and thus through the body, thereby impairing aerobic regeneration of ATP. Therefore, more work is done anaerobically at relatively low workloads and decreased cardiovascular reserve. Thus, a wide range of correlations between CPET parameters, and PVR and CO were seen in all patients in the present study. Not only due to sex difference, different body structures, or because PVR is the product of mPAP and CO, but also because men may have higher baseline mPAP, mRAP and CO \[[@bibr15-1753465816684424]; [@bibr26-1753465816684424]\].

Along with gas exchange inefficiency and metabolic abnormalities, exercise and cardiovascular function are also impaired, which contribute to a decline in CO in IPAH \[[@bibr9-1753465816684424]; [@bibr30-1753465816684424]\]. Peak VO~2~, as a metabolic parameter, assesses the subject's maximal exercise ability and the maximal compensatory ability of the circulatory system to raise CO \[[@bibr29-1753465816684424]\]. The decreased P~ET~CO~2~ in IPAH or cardiac failure patients is considered derived from the ventilation--perfusion mismatch and the increased ratio of physiologic dead space to tidal volume \[[@bibr20-1753465816684424]; [@bibr36-1753465816684424]\]. Peak O~2~ pulse, as a cardiovascular parameter, likely reflects a progressive reduction in peak stroke volume paralleling disease severity with its progressive decline \[[@bibr29-1753465816684424]\]. Although the number of female patients was 1.33 times the number of male patients in the present study, the multivariate analyses of all patients showed similar results to that of men, suggesting that all patients perhaps have more severe gas exchange inefficiency and metabolic abnormalities than cardiovascular abnormalities. Multivariate analyses also indicated that peak P~ET~CO~2~ and VO~2~ were associated most with PVR elevation and CO decline in male patients with IPAH. These results demonstrate that men may have worse gas exchange efficiency and metabolic abnormalities. Peak O~2~ pulse can be considered as independent predictor of PVR elevation and CO decline in female patients, suggesting women may have worse cardiovascular dysfunction. Interestingly, peak P~ET~CO~2~ was an independent predictor of increased PVR in all patients, while peak VO~2~ was also an independent predictor of CO decline in such patients. However, the exact reason why men and women had different results on multivariate analyses needs to be further explored, and whether sex hormones contribute to this also needs further research.

IPAH patients included in this study were small, and without further PAH subgroup classification, that is, FPAH, CTD-PAH, CHD-PAH. Therefore, the sex differences of CPET variables are valid only specifically for IPAH patients for now. Because CPET variables may be abnormal in patients with other PAH subgroups, the independent predictors of increased PVR and decreased CO perhaps could be reflected by other CPET variables in those disease groups as well. In addition, other factors, that is, race and genetic predisposition, could influence metabolic, ventilatory and exercise capacity, but were not considered in the present study.

In summary, our findings suggest that several CPET indexes showed 'sex-specific' differences and some of them could also predict PVR and CO independently. Further validation of these sex differences are needed from larger samples of PAH patients to determine if sex hormones contribute to the difference in CPET variables.
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